Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

NCT06189820 is registered in ClinicalTrials.gov with Erasme University Hospital as lead sponsor.

NCT NCT06189820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06189820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Lead sponsor
Erasme University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 9, 2023
Completion date
March 9, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fap, idiopathic pulmonary fibrosis, lung fibrosis, pulmonary fibrosis